Association between cumulative rATG induction doses and kidney graft outcomes and adverse effects in kidney transplant patients: a systematic review and meta-analysis

References

• Saran R, Robinson B, Abbott KC, et al. US renal data system 2016 annual data report: epidemiology of kidney disease in the United States. Am J Kidney Dis. 2017;69(3):A7–8.
   Web of Science ®Google Scholar
• Akchurin OM. Chronic kidney disease and dietary measures to improve outcomes. Pediatr Clin North Am. 2019;66(1):247–267.
   PubMed Web of Science ®Google Scholar
• Santos C, Costa R, Malheiro J, et al. Kidney transplantation across a positive crossmatch: a single-center experience. Transplant Proc. 2014;46(6):1705–1709.
   PubMed Web of Science ®Google Scholar
• Koyawala N, Silber JH, Rosenbaum PR, et al. Comparing outcomes between antibody induction therapies in kidney transplantation. J Am Soc Nephrol. 2017;28(7):2188–2200.
   PubMed Web of Science ®Google Scholar
• Charpentier B, Rostaing L, Berthoux F, et al. A three-arm study comparing immediate tacrolimus therapy with antithymocyte globulin induction therapy followed by tacrolimus or cyclosporine A in adult renal transplant recipients. Transplantation. 2003;75(6):844–851.
   PubMed Web of Science ®Google Scholar
• Szczech LA, Berlin JA, Aradhye S, et al. Effect of anti-lymphocyte induction therapy on renal allograft survival: a meta-analysis. J Am Soc Nephrol. 1997;8(11):1771–1777.
   PubMed Web of Science ®Google Scholar
• Mourad G, Garrigue V, Squifflet J-P, et al. Induction versus noninduction in renal transplant recipients with tacrolimus-based immunosuppression. Transplantation. 2001;72(6):1050–1055.
   PubMed Web of Science ®Google Scholar
• Casale JP, Taber DJ, Staino C, et al. Effectiveness of an evidence-based induction therapy protocol revision in adult kidney transplant recipients. Pharmacotherapy. 2017;37(6):692–699.
   PubMed Web of Science ®Google Scholar
• Hart A, Smith JM, Skeans MA, et al. OPTN/SRTR 2015 annual data report: kidney. Am J Transplant. 2017;17(Suppl 1):21–116.
   PubMed Web of Science ®Google Scholar
• Kwon Y, Lee KW, Park H, et al. Comparative study of human and cynomolgus T-cell depletion with rabbit anti-thymocyte globulin (rATG) treatment-for dose adjustment in a non-human primate kidney transplantation model. Am J Transl Res. 2019;11(10):6422–6432.
   PubMed Web of Science ®Google Scholar
• Kho MM, Bouvy AP, Cadogan M, et al. The effect of low and ultra-low dosages Thymoglobulin on peripheral T, B and NK cells in kidney transplant recipients. Transpl Immunol. 2012;26(4):186–190.
   PubMed Web of Science ®Google Scholar
• Brennan DC, Flavin K, Lowell JA, et al. A randomized, double-blinded comparison of thymoglobulin versus atgam for induction immunosuppressive therapy in adult renal transplant recipients. Transplantation. 1999;67(7):1011–1018.
   PubMed Web of Science ®Google Scholar
• Agha IA, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation. 2002;73(3):473–475.
   PubMed Web of Science ®Google Scholar
• Gaber AO, First MR, Tesi RJ, et al. Results of the double-blind, randomized, multicenter, phase III clinical trial of Thymoglobulin versus Atgam in the treatment of acute graft rejection episodes after renal transplantation. Transplantation. 1998;66(1):29–37.
   PubMed Web of Science ®Google Scholar
• Malvezzi P, Jouve T, Rostaing L. Induction by anti-thymocyte globulins in kidney transplantation: a review of the literature and current usage. J Nephropathol. 2015;4(4):110–115.
   PubMedGoogle Scholar
• Nafar M, Dalili N, Poor-Reza-Gholi F, et al. The appropriate dose of thymoglobulin induction therapy in kidney transplantation. Clin Transplant. 2017;31(6):6.
   Web of Science ®Google Scholar
• Wong W, Agrawal N, Pascual M, et al. Comparison of two dosages of thymoglobulin used as a short-course for induction in kidney transplantation. Transpl Int. 2006;19(8):629–635.
   PubMed Web of Science ®Google Scholar
• Khanmoradi K, Knorr JP, Feyssa EL, et al. Evaluating safety and efficacy of rabbit antithymocyte globulin induction in elderly kidney transplant recipients. Exp Clin Transplant. 2013;11(3):222–228.
   PubMed Web of Science ®Google Scholar
• Peddi VR, Bryant M, Roy-Chaudhury P, et al. Safety, efficacy, and cost analysis of thymoglobulin induction therapy with intermittent dosing based on CD3+ lymphocyte counts in kidney and kidney-pancreas transplant recipients. Transplantation. 2002;73(9):1514–1518.
   PubMed Web of Science ®Google Scholar
• Singh N, Rossi AP, Savic M, et al. Tailored rabbit antithymocyte globulin induction dosing for kidney transplantation. Transplant Direct. 2018;4(2):e343.
   PubMed Web of Science ®Google Scholar
• Moher D, Liberati A, Tetzlaff J, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Bmj. 2009;339:b2535.
   PubMed Web of Science ®Google Scholar
• Stang A. Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses. Eur J Epidemiol. 2010;25(9):603–605.
   PubMed Web of Science ®Google Scholar
• Higgins JP, Altman DG, Gotzsche PC, et al. The Cochrane collaboration’s tool for assessing risk of bias in randomised trials. Bmj. 2011;343:d5928.
   PubMed Web of Science ®Google Scholar
• Hozo SP, Djulbegovic B, Hozo I. Estimating the mean and variance from the median, range, and the size of a sample. BMC Med Res Methodol. 2005;5:13.
   PubMedGoogle Scholar
• Vella J, Brennan DC. Kidney transplantation in adults: induction immunosuppressive therapy. UpToDate, Post, TW (Ed), UpToDate, Waltham, MA. 2021. Available from: https://www.uptodate.com/contents/kidney-transplantation-in-adults-induction-immunosuppressive-therapy.
   Google Scholar
• Kim Y, Kang SS, Park WY, et al. Optimal dose of thymoglobulin for induction therapy in high risk kidney transplant recipients.J Korean Soc Transplant. 2016;30(2):82-85.
   Google Scholar
• Liu HY, Cheng Y-T, Luo HL, et al. Modest dose anti-thymocyte globulin administered intraoperatively is safe and effective in kidney transplantations: a retrospective study. PeerJ. 2019;7:e7274.
   PubMed Web of Science ®Google Scholar
• Ata P, Kara M, Özdemir E, et al. Monitoring of CD3+ T-cell count in patients receiving antithymocyte globulin induction after cadaveric renal transplantation. Transplant Proc. 2013;45(3):929–931.
   PubMed Web of Science ®Google Scholar
• Grafals M, Smith B, Murakami N, et al. Immunophenotyping and efficacy of low dose ATG in non-sensitized kidney recipients undergoing early steroid withdrawal: a randomized pilot study. PLoS One. 2014;9(8):e104408.
   PubMed Web of Science ®Google Scholar
• Esposito L, Kamar N, Durand D, et al. Comparison of induction based on continuous vs discontinuous administration of antithymocyte globulins in renal transplant patients: efficacy and long-term safety. Transplant Proc. 2005;37(2):892–894.
   PubMed Web of Science ®Google Scholar
• Gurk-Turner C, Airee R, Philosophe B, et al. Thymoglobulin dose optimization for induction therapy in high risk kidney transplant recipients. Transplantation. 2008;85(10):1425–1430.
   PubMed Web of Science ®Google Scholar
• Harrison JJ, Hamandi B, Li Y, et al. Timing of rabbit antithymocyte globulin induction therapy in kidney transplantation: an observational cohort study. Transplant Res. 2014;3(1):1.
   PubMedGoogle Scholar
• Klem P, Cooper JE, Weiss AS, et al. Reduced dose rabbit anti-thymocyte globulin induction for prevention of acute rejection in high-risk kidney transplant recipients. Transplantation. 2009;88(7):891–896.
   PubMed Web of Science ®Google Scholar
• Marfo K, Akalin E, Wang C, et al. Clinical and economic analysis of short-course versus standard-course antithymocyte globulin (rabbit) induction therapy in deceased-donor renal transplant recipients. Am J Health Syst Pharm. 2011;68(23):2276–2282.
   PubMed Web of Science ®Google Scholar
• Patel SJ, Knight RJ, Suki WN, et al. Rabbit antithymocyte induction and dosing in deceased donor renal transplant recipients over 60 yr of age. Clin Transplant. 2011;25(3):E250–6.
   PubMed Web of Science ®Google Scholar
• Pennington CA, Tischer SM, Lee E, et al. Evaluation of a weight-based rabbit anti-thymocyte globulin induction dosing regimen for kidney transplant recipients. Pharmacotherapy. 2015;35(8):748–754.
   PubMed Web of Science ®Google Scholar
• Rogers CC, Asipenko N, Horwedel T, et al. Renal transplantation in the setting of early steroid withdrawal: a comparison of rabbit antithymocyte globulin induction dosing in two eras. Am J Nephrol. 2013;38(5):397–404.
   PubMed Web of Science ®Google Scholar
• Tenney JW, Mokaddem S, Shah V, et al. Antithymocyte globulin dosing effects on biopsy-proven acute rejection and infection risk. Ann Transplant. 2015;20:285–289.
   PubMed Web of Science ®Google Scholar
• Trofe-Clark J, Reese PP, Patel HJ, et al. Efficacy and safety of extended-duration inpatient-to-outpatient rabbit antithymocyte globulin induction in de novo kidney transplant recipients: 6-month outcomes. Transplantation. 2012;94(5):506–512.
   PubMed Web of Science ®Google Scholar
• Tsapepas DS, Mohan S, Tanriover B, et al. Impact of small variations in the delivered dose of rabbit antithymocyte induction therapy in kidney transplantation with early corticosteroid withdrawal. Transplantation. 2012;94(4):325–330.
   PubMed Web of Science ®Google Scholar
• Vacha M, Gommer J, Rege A, et al. Effects of ideal versus total body weight dosage of rabbit antithymocyte globulin on outcomes of kidney transplant patients with high immunologic risk. Exp Clin Transplant. 2016;14(5):511–517.
   PubMed Web of Science ®Google Scholar
• Yang JW, Wang JN, Men TY, et al. Comparison of clinical outcome of low-dose and high-dose rabbit antithymocyte globulin induction therapy in renal transplantation: a single-center experience. Ann Transplant. 2014;19:277–282.
   PubMed Web of Science ®Google Scholar
• Djamali A, Turc-Baron C, Portales P, et al. Low dose antithymocyte globulins in renal transplantation: daily versus intermittent administration based on T-cell monitoring. Transplantation. 2000;69(5):799–805.
   PubMed Web of Science ®Google Scholar
• Laftavi MR, Patel S, Soliman MR, et al. Low-dose thymoglobulin use in elderly renal transplant recipients is safe and effective induction therapy. Transplant Proc. 2011;43(2):466–468.
   PubMed Web of Science ®Google Scholar
• Thervet E, Chatenoud L, Legendre C, et al. Clinical significance of T cell monitoring during antithymocyte globulin induction in renal transplantation. Transplant Proc. 1997;29(5):2330–2331.
   PubMed Web of Science ®Google Scholar
• Blazquez-Navarro A, Dang-Heine C, Wittenbrink N, et al. BKV, CMV, and EBV interactions and their effect on graft function one year post-renal transplantation: results from a large multi-centre study. EBioMedicine. 2018;34:113–121.
   PubMed Web of Science ®Google Scholar